Biogen Inc. (NASDAQ: BIIB) announced Tuesday new data from its robust multiple sclerosis (MS) treatment portfolio. Additional clinical data support VUMERITY® (diroximel fumarate) as an important oral treatment option in relapsing MS and reinforce the efficacy of TECFIDERA® (dimethyl fumarate). In addition, an analysis of TYSABRI® (natalizumab) contributes to data demonstrating the reduced risk of progressive multifocal leukoencephalopathy (PML) through extended interval dosing (EID; approximately every six weeks) as compared to the currently approved dosing of every four weeks. These new data were selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting and will be available online via the 2020 AAN Science Highlights virtual platform.
“We continue to lead in MS with new data that demonstrate the strength of our portfolio and Biogen’s commitment to enhancing the care of individuals with relapsing MS,” said Bernd Kieseier, M.D., MHBA, Executive Director, Head of Global MS, Worldwide Medical, Biogen. “The data shared at AAN represent our ongoing efforts to improve the MS treatment experience and deliver therapies that provide clinically meaningful benefits to individuals living with this chronic disease.”
In an analysis of data from the double-blind, randomized, Phase 3 EVOLVE-MS-2 study, patients treated with VUMERITY or TECFIDERA (n=295) demonstrated a significant reduction in gadolinium-enhancing (Gd+) lesion counts as early as seven weeks after treatment initiation. After continuing treatment with VUMERITY in the ongoing, open-label, Phase 3 EVOLVE-MS-1 study (n=82), researchers observed that 96.3 percent of patients were free from Gd+ lesions after one year. Both TECFIDERA and VUMERITY have shown early and sustained efficacy in patients with relapsing-remitting MS (RRMS).
Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.